TargetMol

Fenirofibrate

Product Code:
 
TAR-T31771
Product Group:
 
Inhibitors and Activators
Supplier:
 
TargetMol
Regulatory Status:
 
RUO
Shipping:
 
cool pack
Storage:
 
-20℃
1 / 1
❮❯

No additional charges, what you see is what you pay! *

CodeSizePrice
TAR-T31771-5mg5mg£271.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT
How to order with us   Contact us
Stay in control of your spending. These prices have no additional charges, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: United States.
Typical lead time: 10-14 working days.
Contact us for more accurate information.
  • Further Information
  • Documents
  • References
  • Show All

Further Information

Bioactivity:
Fenirofibrate is a metabolite of Fenofibrate.
CAS:
54419-31-7
Formula:
C17H17ClO4
Molecular Weight:
320.77
Purity:
0.98
SMILES:
CC(C)(Oc1ccc(cc1)C(O)c1ccc(Cl)cc1)C(O)=O

References

1. Xu H, Han Y, Lou J, Zhang H, Zhao Y, Gy?rffy B, Li R. PDGFRA, HSD17B4 and HMGB2 are potential therapeutic targets in polycystic ovarian syndrome and breast cancer. Oncotarget. 2017 May 13. doi: 10.18632/oncotarget.17846. [Epub ahead of print] PubMed PMID: 28562323. 2. Kim TK. Determination of Fenofibric Acid in Rat Plasma and its Application to a Comparative Pharmacokinetic Study of JW322 and Fenofibrate. Drug Res (Stuttg). 2017 May 30. doi: 10.1055/s-0043-109243. [Epub ahead of print] PubMed PMID: 28561239. 3. Du L, Ma Y, Liu M, Yan L, Tang H. Peroxisome Proliferators Activated Receptor (PPAR) agonists activate hepatitis B virus replication in vivo. Virol J. 2017 May 25;14(1):96. doi: 10.1186/s12985-017-0765-x. PubMed PMID: 28545573; PubMed Central PMCID: PMC5445479. 4. M?ller-Wieland D, Leiter LA, Cariou B, Letierce A, Colhoun HM, Del Prato S, Henry RR, Tinahones FJ, Aurand L, Maroni J, Ray KK, Bujas-Bobanovic M. Design and rationale of the ODYSSEY DM-DYSLIPIDEMIA trial: lipid-lowering efficacy and safety of alirocumab in individuals with type 2 diabetes and mixed dyslipidaemia at high cardiovascular risk. Cardiovasc Diabetol. 2017 May 25;16(1):70. doi: 10.1186/s12933-017-0552-4. PubMed PMID: 28545518; PubMed Central PMCID: PMC5445362.